BioCardia (NASDAQ:BCDA – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of current recommendations and price targets for BioCardia and MDxHealth, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| MDxHealth | 1 | 4 | 1 | 0 | 2.00 |
BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,556.75%. MDxHealth has a consensus price target of $1.33, suggesting a potential upside of 800.90%. Given BioCardia’s higher possible upside, equities analysts plainly believe BioCardia is more favorable than MDxHealth.
Profitability
This table compares BioCardia and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -569.36% | -183.15% |
| MDxHealth | -33.46% | N/A | -24.25% |
Insider & Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
BioCardia has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
Valuation & Earnings
This table compares BioCardia and MDxHealth”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $60,000.00 | 237.45 | -$8.23 million | ($0.64) | -1.47 |
| MDxHealth | $107.88 million | 0.07 | -$33.52 million | ($0.72) | -0.21 |
BioCardia has higher earnings, but lower revenue than MDxHealth. BioCardia is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Summary
BioCardia beats MDxHealth on 7 of the 12 factors compared between the two stocks.
About BioCardia
BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy. BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.
About MDxHealth
MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning. MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
